Serpina3n accelerates tissue repair in a diabetic mouse model of delayed wound healing

Cell Death and Disease

Volumn 5, Issue 10, 2014, Pages

  Hsu, I ^a   Parkinson, L M ^a   Shen, Y ^a   Toro, A ^a   Brown, T ^a   Zhao, H ^a   Bleackley, R C ^b   Granville, D J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FIBRONECTIN; GRANZYME B; SERINE PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR SERPINA3N; UNCLASSIFIED DRUG; ACUTE PHASE PROTEIN; GRANZYME; SERPINA3N PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIZATION; EXTRACELLULAR MATRIX; FIBROBLAST; GRANULATION TISSUE; HOMOGENATE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SKIN BLOOD FLOW; SKIN INJURY; TISSUE REPAIR; WOUND CLOSURE; WOUND HEALING IMPAIRMENT; ANIMAL; C57BL MOUSE; DISEASE MODEL; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; GENETICS; HUMAN; INJURIES; MALE; METABOLISM; PATHOPHYSIOLOGY; SKIN; VASCULARIZATION; WOUND HEALING;

MURINAE; MUS;

ACUTE-PHASE PROTEINS; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLLAGEN; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; GRANZYMES; HUMANS; MALE; MICE; MICE, INBRED C57BL; SERPINS; SKIN; WOUND HEALING;

EID: 84922717655     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.423     Document Type: Article

References (61)

1. Ramsey S, Sandhu N, Newton K, Reiber G, Blough D, Wagner E et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care 1999; 22: 382-387.
2. Singh N, Armstrong D, Lipsky B. Preventing foot ulcers in patients with diabetes. J Am Med Assoc 2005; 293: 217-228.
3. Veves A, Sheehan P, Pham H. A randomized, controlled trial of promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg 2002; 137: 822-827.
4. Blume PA, Walters J, Payne W, Ayala J, Lantis J. Comparison of negative pressure wound therapy using vacuum-assisted closure with advanced moist wound therapy in the treatment of diabetic foot ulcers: a multicenter randomized controlled trial. Diabetes Care 2008; 31: 631-636.
5. Wunderlich R, Peters E, Lavery L. Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot. Diabetes Care 2000; 23: 1551-1555.
6. Falanga V. Wound healing and its impairment in the diabetic foot. Lancet 2005; 366: 1736-1743.
7. Schultz GS, Wysocki A. Interactions between extracellular matrix and growth factors in wound healing. Wound Repair Regen 2009; 17: 153-162.
8. Ravanti L, Kahari V. Matrix metalloproteinases in wound repair (Review). Int J Mol Med 2000; 6: 391-407.
9. Dufour A, Overall CM. Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol Sci 2013; 34: 233-242.
10. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008; 29: 290-308.
11. Masson D, Tschopp J. A family of serine esterases in lytic granules of cytolytic T lymphocytes. Cell 1987; 49: 679-685.
12. Boivin WA, Cooper DM, Hiebert PR, Granville DJ. Intracellular versus extracellular granzyme B in immunity and disease: challenging the dogma. Lab Invest 2009; 89: 1195-1220.
13. Chamberlain CM, Ang LS, Boivin WA, Cooper DM, Williams SJ, Zhao H et al. Perforin-independent extracellular granzyme B activity contributes to abdominal aortic aneurysm. Am J Pathol 2010; 176: 1038-1049.
14. Hiebert PR, Boivin WA, Abraham T, Pazooki S, Zhao H, Granville DJ. Granzyme B contributes to extracellular matrix remodeling and skin aging in apolipoprotein E knockout mice. Exp Gerontol 2011; 46: 489-499.
15. Hiebert PR, Boivin WA, Zhao H, McManus BM, Granville DJ. Perforin and granzyme B have separate and distinct roles during atherosclerotic plaque development in apolipoprotein E knockout mice. PLoS One 2013; 8: e78939.
16. Hiebert PR, Wu D, Granville DJ. Granzyme B degrades extracellular matrix and contributes to delayed wound closure in apolipoprotein E knockout mice. Cell Death Differ 2013; 20: 1404-1414.
17. Grinnell F. Fibronectin and wound healing. J Cell Biochem 1984; 26: 107-116.
18. Silverman G, Bird P, Carrell R, Church F, Coughlin P, Gettins P et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins - evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001; 276: 33293-33296.
19. Horvath A, Irving J, Rossjohn J, Law R, Bottomley S, Quinsey N et al. The murine orthologue of human antichymotrypsin - a structural paradigm for CLADE A3 serpins. J Biol Chem 2005; 280: 43168-43178.
20. Ang LS, Boivin WA, Williams SJ, Zhao H, Abraham T, Carmine-Simmen K et al. Serpina3n attenuates granzyme B-mediated decorin cleavage and rupture in a murine model of aortic aneurysm. Cell Death Dis 2011; 2: e209.
21. Sipione S, Simmen KC, Lord SJ, Motyka B, Ewen C, Shostak I et al. Identification of a novel human granzyme B inhibitor secreted by cultured Sertoli cells. J Immunol 2006; 177: 5051-5058.
22. Cullen SP, Martin SJ. Mechanisms of granule-dependent killing. Cell Death Differ 2008; 15: 251-262.
23. Simon M, Hoschutzky H, Fruth U, Simon H, Kramer M. Purification and characterization of a T-cell specific serine proteinase (Tsp-1) from cloned cytolytic T lymphocytes. EMBO J 1986; 5: 3267-3274.
24. Boivin WA, Shackleford M, Vanden Hoek A, Zhao H, Hackett TL, Knight DA et al. Granzyme B cleaves decorin, biglycan and soluble betaglycan, releasing active transforming growth factor-beta 1. PLoS One 2012; 7: e33163.
25. Susanto O, Trapani JA, Brasacchio D. Controversies in granzyme biology. Tissue Antigens 2012; 80: 477-487.
26. Ewen CL, Kane KP, Bleackley RC. A quarter century of granzymes. Cell Death Differ 2012; 19: 28-35.
27. Afonina IS, Cullen SP, Martin SJ. Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B. Immunol Rev 2010; 235: 105-116.
28. Young L, Joag S, Lin P, Luo S, Zheng L, Liu C et al. Expression of cytolytic mediators by synovial-fluid lymphocytes in rheumatoid-arthritis. Am J Pathol 1992; 140: 1261-1268.
29. Tak P, Spaeny-Dekking L, Kraan M, Breedveld F, Froelich C, Hack C. The levels of soluble granzyme A and B are elevated in plasma and synovial fluid of patients with rheumatoid arthritis (RA). Clin Exp Immunol 1999; 116: 366-370.
30. Malmestrom C, Lycke J, Haghighi S, Andersen O, Carlsson L, Wadenvik H et al. Relapses in multiple sclerosis are associated with increased CD8(+) T-cell mediated cytotoxicity in CSF. J Neuroimmunol 2008; 196: 159-165.
31. Schneider R, Mohebiany AN, Ifergan I, Beauseigle D, Duquette P, Prat A et al. B Cell-derived IL-15 enhances CD8 T cell cytotoxicity and is increased in multiple sclerosis patients. J Immunol 2011; 187: 4119-4128.
32. Omoto Y, Yamanaka K, Tokime K, Kitano S, Kakeda M, Akeda T et al. Granzyme B is a novel interleukin-18 converting enzyme. J Dermatol Sci 2010; 59: 129-135.
33. Takahashi Y, Mine J, Kubota Y, Yamazaki E, Fujiwara T. A substantial number of Rasmussen syndrome patients have increased IgG, CD4(+) T cells, TNF alpha, and Granzyme B in CSF. Epilepsia 2009; 50: 1419-1431.
34. Bratke K, Bottcher B, Leeder K, Schmidt S, Kupper M, Virchow J et al. Increase in granzyme B+ lymphocytes and soluble granzyme B in bronchoalveolar lavage of allergen challenged patients with atopic asthma. Clin Exp Immunol 2004; 136: 542-548.
35. Buzza M, Zamurs L, Sun J, Bird C, Smith A, Trapani J et al. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin, and laminin. J Biol Chem 2005; 280: 23549-23558.
36. Froelich C, Zhang X, Turbov J, Hudig D, Winkler U, Hanna W. Human granzyme-B degrades aggrecan proteoglycan in matrix synthesized by chondrocytes. J Immunol 1993; 151: 7161-7171.
37. Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen 2009; 17: 763-771.
38. Schultz GS, Davidson JM, Kirsner RS, Bornstein P, Herman IM. Dynamic reciprocity in the wound microenvironment. Wound Repair Regen 2011; 19: 134-148.
39. Wysocki A, Staianocoico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases Mmp-2 and Mmp-9. J Invest Dermatol 1993; 101: 64-68.
40. Trengove N, Stacey M, Macauley S, Bennett N, Gibson J, Burslem F et al. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999; 7: 442-452.
41. Moor AN, Vachon DJ, Gould LJ. Proteolytic activity in wound fluids and tissues derived from chronic venous leg ulcers. Wound Repair Regen 2009; 17: 832-839.
42. Palolahti M, Lauharanta J, Stephens RW, Kuusela P, Vaheri A. Proteolytic activity in leg ulcer exudate. Exp Dermatol 1993; 2: 29-37.
43. Cullen B, Smith R, McCulloch E, Silcock D, Morrison L. Mechanism of action of PROMOGRAN, a protease modulating matrix, for the treatment of diabetic foot ulcers. Wound Repair Regen 2002; 10: 16-25.
44. Grinnell F, Zhu M. Fibronectin degradation in chronic wounds depends on the relative levels of elastase, alpha 1-proteinase inhibitor, and alpha 2-macroglobulin. J Invest Dermatol 1996; 106: 335-341.
45. Schmidtchen A. Degradation of antiproteinases, complement and fibronectin in chronic leg ulcers. Acta Derm Venereol 2000; 80: 179-184.
46. Stanley CM,Wang Y, Pal S, Klebe RJ, Harkless LB, Xu X et al. Fibronectin fragmentation is a feature of periodontal disease sites and diabetic foot and leg wounds and modifies cell behavior. J Periodontol 2008; 79: 861-875.
47. Rao CN, Ladin DA, Liu YY, Chilukuri K, Hou ZZ, Woodley DT. Alpha 1-antitrypsin is degraded and non-functional in chronic wounds but intact and functional in acute wounds: the inhibitor protects fibronectin from degradation by chronic wound fluid enzymes. J Invest Dermatol 1995; 105: 572-578.
48. Grinnell F, Ho C, Wysocki A. Degradation of fibronectin and vitronectin in chronic wound fluid- analysis by cell blotting, immunoblotting, and cell-adhesion assays. J Invest Dermatol 1992; 98: 410-416.
49. Wysocki A, Grinnell F. Fibronectin profiles in normal and chronic wound fluid. Lab Invest 1990; 63: 825-831.
50. Hendel A, Granville DJ. Granzyme B cleavage of fibronectin disrupts endothelial cell adhesion, migration and capillary tube formation. Matrix Biol 2013; 32: 14-22.
51. Gailit J, Clark R. Studies in vitro on the role of alpha v and beta 1 integrins in the adhesion of human dermal fibroblasts to provisional matrix proteins fibronectin, vibronectin, and fibrinogen. J Invest Dermatol 1996; 106: 102-108.
52. Desmouliere A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth-factor-beta-1 induces alpha-smooth muscle actin expression in granulation-tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J Cell Biol 1993; 122: 103-111.
53. Desmouliere A, Chaponnier C, Gabbiani G. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen 2005; 13: 7-12.
54. To WS, Midwood KS. Plasma and cellular fibronectin: distinct and independent functions during tissue repair. Fibrogenesis Tissue Repair 2011; 4: 1536-4-21.
55. Darby I, Sk O, Gabbiani G. Alpha-smooth muscle actin is transiently expressed by myofibroblasts during experimental wound-healing. Lab Invest 1990; 63: 21-29.
56. Serini G, Bochaton-Piallat M, Ropraz P, Geinoz A, Borsi L, Zardi L et al. The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta 1. J Cell Biol 1998; 142: 873-881.
57. Stanley A, Park H, Phillips T, Russakovsky V, Menzoian J. Reduced growth of dermal fibroblasts from chronic venous ulcers can be stimulated with growth factors. J Vasc Surg 1997; 26: 994-999.
58. Raffetto J, Mendez M, Phillips T, Park H, Menzoian J. The effect of passage number on fibroblast cellular senescence in patients with chronic venous insufficiency with and without ulcer. Am J Surg 1999; 178: 107-112.
59. Agren M, Steenfos H, Dabelsteen S, Hansen J, Dabelsteen E. Proliferation and mitogenic response to PDGF-BB of fibroblasts isolated from chronic venous leg ulcers is ulcer-age dependent. J Invest Dermatol 1999; 112: 463-469.
60. Vande Berg J, Rose M, Haywood-Reid P, Rudolph R, Payne W, Robson M. Cultured pressure ulcer fibroblasts show replicative senescence with elevated production of plasmin, plasminogen activator inhibitor-1, and transforming growth factor-beta 1. Wound Repair Regen 2005; 13: 76-83.
61. Hendel A, Hsu I, Granville DJ. Granzyme B releases vascular endothelial growth factor from extracellular matrix and induces vascular permeability. Lab Invest 2014; 94: 716-725.